Hokyung K Chung1, Conor L Jacobs1, Yunwen Huo2, Jin Yang3, Stefanie A Krumm4, Richard K Plemper4,5, Roger Y Tsien3,6,7 & Michael Z Lin2,8*
1Department of Biology, Stanford University, Stanford, California, USA. 2Department of Pediatrics, Stanford University, Stanford, California, USA. 3Department of Pharmacology, University of California, San Diego, La Jolla, California, USA. 4Department of Pediatrics, Emory University, Atlanta, Georgia, USA. 5Institute for Biomedical Sciences, Georgia State University, Atlanta, Georgia, USA. 6Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla, California, USA. 7Howard Hughes Medical Institute, University of California, San Diego, La Jolla, California, USA. 8Department of Bioengineering, Stanford University, Stanford, California, USA.
*Correspondence to : Michael Z Lin
Abstract
An effective method for direct chemical control over the production of specific proteins would be widely useful. We describe small molecule-assisted shutoff (SMASh), a technique in which proteins are fused to a degron that removes itself in the absence of drug, resulting in the production of an untagged protein. Clinically tested HCV protease inhibitors can then block degron removal, inducing rapid degradation of subsequently synthesized copies of the protein. SMASh allows reversible and dose-dependent shutoff of various proteins in multiple mammalian cell types and in yeast. We also used SMASh to confer drug responsiveness onto an RNA virus for which no licensed inhibitors exist. As SMASh does not require the permanent fusion of a large domain, it should be useful when control over protein production with minimal structural modification is desired. Furthermore, as SMASh involves only a single genetic modification and does not rely on modulating protein-protein interactions, it should be easy to generalize to multiple biological contexts.